Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis
- 1 March 2016
- journal article
- research article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (2) , 145-149
Abstract
TNM staging is mainly used to evaluate the prognosis of melanoma patients. Serum biomarkers such as 5‐S‐cysteinyldopa (5‐S‐CD) have occasionally been used but most do not respond until the tumour burden becomes high. Recently, circulating melanoma cells (CMC) have been reported as a possible new biomarker to detect metastasis, monitor treatment response and predict prognosis. The object of this exploratory study was to evaluate the efficacy of CMC to detect metastasis and predict prognosis by cross‐sectional and prospective observational analyses, respectively. Altogether 15 patients with stages II–IV melanoma were enrolled and CMC were enumerated by CellSearch system with cut‐off values of two cells/7.5 mL. Serum 5‐S‐CD and lactate dehydrogenase (LDH) were also measured. The sensitivity of CMC and 5‐S‐CD for the detection of metastasis was 33 and 50%, respectively. The combination of CMC and 5‐S‐CD showed a sensitivity of 67%, the best performance among CMC, 5‐S‐CD, LDH and any combination of two of the markers. Additionally, a 30‐month prospective observation showed that CMC could segregate patients with poorer prognosis. The median survival time for the patients with <2 CMC and those with ≥2 CMC was 19.5 and 4.5 months, respectively. The limitation of this study is the small sample size. These preliminary results indicate CMC may complement the efficacy of 5‐S‐CD to detect metastasis and can be a prognostic marker. Although there is still room for improvement to maximise the sensitivity, the CellSearch system is reproducible, standardised and suitable for multi‐centre studies.Keywords
This publication has 15 references indexed in Scilit:
- Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to TreatmentJournal of Investigative Dermatology, 2015
- Detection methods of circulating tumor cells in cutaneous melanoma: A systematic reviewCritical Reviews in Oncology/Hematology, 2014
- Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanomaMelanoma Research, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Circulating Melanoma Cells as a Predictive BiomarkerJournal of Investigative Dermatology, 2013
- Recent advances in cutaneous melanoma: towards a molecular model and targeted treatmentAustralasian Journal of Dermatology, 2013
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivoInternational Journal of Oncology, 2011
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agentsAnnals of Oncology, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009